Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHX-896 bioequivalence study in schizophrenia and bipolar I disorder
NCT06494397Phase 1Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of milsaperidone in schizophrenia and bipolar I disorder (2 arms), sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Bioequivalence between VHX-896 tablets relative to iloperidone tablets at 12 hours. Started Jul 2024; status: completed.
02
Drugs
milsaperidone
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT06494397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494397.